Psychedelics are being pulled into the mainstream by medical research (9:00). Filament Health CEO Benjamin Lightburn on Psilocybin and why of all the psychedelics it probably lends itself best to a recreational market (15:00). Microdosing clinical trials (19:00) real revenue generation (28:00) and challenges around psychedelic patents (33:30).

Our links:
The Cannabis Investing Podcast
The Cannabis Investing Podcast provides actionable investment insight and the context with which to understand the burgeoning cannabis industry. All transcripts can be found on Seeking Alpha.

Seeking Alpha Premium
A comprehensive set of features and analysis that helps take the guesswork out of your investing decisions. Get the bottom-line on any stock or ETF with our Premium tools.

CanPod on Twitter

Show links:
Filament Health
FLHLF